[Skip to Content]
[Skip to Content Landing]
Invited Commentary
June 2017

Mitigating Financial Toxicity Among US Patients With Cancer

Author Affiliations
  • 1Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois
  • 2Department of Pediatrics, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois
  • 3Department of Public Health Sciences, The University of Chicago, Chicago, Illinois
JAMA Oncol. 2017;3(6):765-766. doi:10.1001/jamaoncol.2016.4850

Treatment for cancer is undergoing a renaissance. However, the “financial toxicity” of cancer treatment for US patients and their families is a growing concern.1 Financial distress among patients with cancer includes high out-of-pocket (OOP) spending relative to income and assets, loss of work, and significant household debt. Financial distress is associated with growing reports of delayed initiation of treatment, limited patient adherence, and abandonment of recommended treatment, which erodes the effectiveness of cancer treatment and even hastens death.

First Page Preview View Large
First page PDF preview
First page PDF preview
×